Previous 10 | Next 10 |
Quarterly investor conference call and webcast scheduled for Tuesday, February 27 at 8:30 a.m. ET WESTLAKE VILLAGE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful i...
2024-02-16 07:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is one of today's top gainers. The company's shares have moved 14.91% on the day to $6.55. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product...
2024-02-01 08:29:22 ET More on pre-market losers & stocks. Bullfrog AI stock rallies 32% on early brain research results Infobird announces new business deal in software development of information technology system Financial information for Bullfrog AI Holdings, ...
2024-01-31 17:40:53 ET More on Arcutis Biotherapeutics Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture Mizuho upgrades Arcutis to buy, cites Zoryve sales Read the full article on Seeking Alpha For further details see: Arcutis Biotherapeuti...
WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggen...
2024-01-31 03:09:25 ET Summary Arcutis is a late-stage biopharmaceutical company focused on developing treatments for immune-mediated dermatological diseases. The company has received FDA approval for its topical cream, Zoryve, for the treatment of plaque psoriasis and seborrheic ...
Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE ® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older WESTLAKE VILLAGE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ar...
2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus, ( EOLS ) +2% . SSR Mining ( SSRM ) +2% . Losers: Progress Software ...
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itch Seborrheic dermatitis affects mo...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension ach...